WuXi Biologics (Cayman) Inc. - SIC # 8100 -

Ticker Exchange SIC # Website Latest Ticker
WXXWY Over the counter 8100 www.wuxibiologics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for WuXi Biologics (Cayman) Inc.

WuXi Biologics Extends Global CRDMO Network to Qatar Through Strategic MoU Signed with Qatar Free Zones Authority - Dec 2nd, 2025 1:46 am
WuXi Biologics (SEHK:2269): Exploring Valuation After Recent Turnaround in Share Price Momentum - Nov 11th, 2025 3:13 pm
Whitehawk Therapeutics to Present at Jefferies Global Healthcare Conference in London - Nov 11th, 2025 6:00 am
WuXi Biologics Included in Hang Seng Corporate Sustainability Benchmark Index - Oct 21st, 2025 6:30 pm
WuXi Biologics Honored with 2025 Global Customer Value Leadership Recognition by Frost & Sullivan - Oct 20th, 2025 3:30 am
WuXi Biologics Receives MSCI AAA ESG Rating for Third Consecutive Year - Oct 9th, 2025 6:30 pm
WuXi Biologics (SEHK:2269) Valuation in Focus Following Recent Share Price Gains - Oct 4th, 2025 7:47 am
The 2025 BPD Singapore Conference Has Concluded Successfully! Jointly Embarking on a New Journey for Global Development - Sep 26th, 2025 7:00 pm
WuXi Biologics Launches WuXia™4.0, Targeted Integration Cell Line Platform TrueSite TI™，to Accelerate Biologics Development with High Titer and Superior Stability - Sep 25th, 2025 5:42 am
WuXi Biologics Selected as Constituent of FTSE4Good Index Series for Fifth Consecutive Year - Sep 22nd, 2025 10:00 pm
Three WuXi Biologics Manufacturing Facilities Receive GMP Certification from Türkiye İlaç ve Tıbbi Cihaz Kurumu (TITCK) - Sep 16th, 2025 10:00 pm
China Economy, Fed Outlook Churn Asian Stock Markets - Sep 15th, 2025 4:38 am
WuXi Biologics Achieves "CDMO of the Year" Among Three Prestigious IMAPAC Awards - Sep 11th, 2025 7:30 pm
Does WuXi Biologics Merit a Closer Look After 245% Stock Surge and US Sanctions News? - Sep 9th, 2025 6:01 am
WuXi Biologics Launches Green CRDMO White Paper to Advance Sustainability in Biologics Industry - Sep 9th, 2025 4:00 am
WuXi Biologics' Near-Term and Net-Zero Targets Approved by SBTi - Aug 28th, 2025 3:00 am
WuXi Biologics Reports Solid 2025 Interim Results - Aug 19th, 2025 6:35 am
WuXi Biologics' WuXiUP™ Accomplishes Automated Continuous Drug Substance Production at Pilot-Scale - Aug 12th, 2025 3:00 am
WuXi Biologics Launches HEK 293 Stable Cell Line Platform WuXia293 Stable for Development and Manufacturing of Difficult-to-Express Molecules - Aug 11th, 2025 2:30 am
WuXi Biologics Named to A List for CDP Supplier Engagement Assessment - Aug 6th, 2025 6:30 pm